Jupiter Asset Administration Ltd. bought a brand new stake in Arcus Biosciences, Inc. (NYSE:RCUS – Free Report) within the first quarter, in response to its most up-to-date Type 13F submitting with the Securities & Trade Fee. The fund bought 42,234 shares of the corporate’s inventory, valued at roughly $770,000. Jupiter Asset Administration Ltd. owned about 0.06% of Arcus Biosciences on the finish of the latest reporting interval.
Numerous different institutional traders and hedge funds have additionally just lately purchased and offered shares of the inventory. Arizona State Retirement System lifted its place in Arcus Biosciences by 4.5% within the fourth quarter. Arizona State Retirement System now owns 12,217 shares of the corporate’s inventory valued at $253,000 after buying an extra 523 shares over the past quarter. Mirae Asset International Investments Co. Ltd. lifted its place in Arcus Biosciences by 2.6% within the fourth quarter. Mirae Asset International Investments Co. Ltd. now owns 22,094 shares of the corporate’s inventory valued at $457,000 after buying an extra 551 shares over the past quarter. New York State Lecturers Retirement System lifted its place in Arcus Biosciences by 1.0% within the fourth quarter. New York State Lecturers Retirement System now owns 83,751 shares of the corporate’s inventory valued at $1,732,000 after buying an extra 800 shares over the past quarter. AQR Capital Administration LLC raised its holdings in shares of Arcus Biosciences by 0.7% within the fourth quarter. AQR Capital Administration LLC now owns 120,964 shares of the corporate’s inventory valued at $2,502,000 after shopping for an extra 856 shares over the past quarter. Lastly, Captrust Monetary Advisors raised its holdings in shares of Arcus Biosciences by 402.9% within the second quarter. Captrust Monetary Advisors now owns 2,072 shares of the corporate’s inventory valued at $53,000 after shopping for an extra 1,660 shares over the past quarter. 75.65% of the inventory is owned by hedge funds and different institutional traders.
Insider Exercise at Arcus Biosciences
In associated information, COO Jennifer Jarrett offered 12,437 shares of the agency’s inventory in a transaction dated Thursday, June twenty second. The shares have been offered at a median value of $19.12, for a complete worth of $237,795.44. Following the completion of the sale, the chief working officer now owns 381,566 shares within the firm, valued at $7,295,541.92. The sale was disclosed in a authorized submitting with the SEC, which is obtainable by way of the SEC web site. In associated information, main shareholder Gilead Sciences, Inc. purchased 1,010,000 shares of the corporate’s inventory in a transaction on Wednesday, June twenty eighth. The inventory was purchased at a median value of $19.26 per share, with a complete worth of $19,452,600.00. Following the completion of the acquisition, the insider now owns 14,823,029 shares within the firm, valued at roughly $285,491,538.54. The transaction was disclosed in a submitting with the Securities & Trade Fee, which is obtainable by way of this hyperlink. Additionally, COO Jennifer Jarrett offered 12,437 shares of the inventory in a transaction dated Thursday, June twenty second. The shares have been offered at a median value of $19.12, for a complete transaction of $237,795.44. Following the completion of the transaction, the chief working officer now instantly owns 381,566 shares of the corporate’s inventory, valued at $7,295,541.92. The disclosure for this sale might be discovered right here. Insiders offered a complete of 71,018 shares of firm inventory price $1,412,917 during the last 90 days. Firm insiders personal 13.80% of the corporate’s inventory.
Arcus Biosciences Inventory Efficiency
Shares of NYSE:RCUS opened at $17.62 on Friday. Arcus Biosciences, Inc. has a 52 week low of $15.70 and a 52 week excessive of $36.13. The corporate has a 50-day transferring common value of $19.76 and a 200 day transferring common value of $19.11.
Arcus Biosciences (NYSE:RCUS – Get Free Report) final introduced its quarterly earnings information on Monday, August seventh. The corporate reported ($1.04) EPS for the quarter, beating analysts’ consensus estimates of ($1.10) by $0.06. The agency had income of $29.00 million throughout the quarter, in comparison with the consensus estimate of $31.81 million. Arcus Biosciences had a destructive internet margin of 235.99% and a destructive return on fairness of 45.51%. The agency’s income was up 7.4% in comparison with the identical quarter final 12 months. Throughout the identical quarter final 12 months, the agency earned ($0.93) earnings per share. On common, analysis analysts forecast that Arcus Biosciences, Inc. will submit -4.3 EPS for the present fiscal 12 months.
Wall Avenue Analysts Forecast Progress
RCUS has been the topic of numerous analysis reviews. Morgan Stanley lowered their goal value on shares of Arcus Biosciences from $40.00 to $38.00 and set an “chubby” ranking for the corporate in a report on Tuesday, August eighth. Citigroup upped their goal value on shares of Arcus Biosciences from $40.00 to $41.00 in a report on Friday, Might twenty sixth. One equities analysis analyst has rated the inventory with a maintain ranking and 6 have assigned a purchase ranking to the corporate. In accordance with information from MarketBeat.com, the corporate has a consensus ranking of “Average Purchase” and a median value goal of $39.50.
View Our Newest Inventory Evaluation on Arcus Biosciences
Arcus Biosciences Profile
(Free Report)
Arcus Biosciences, Inc, a clinical-stage biopharmaceutical firm, develops and commercializes most cancers therapies in america. The corporate’s pipeline merchandise embrace Domvanalimab, an anti-TIGIT investigational monoclonal antibody, which is in Part 2 and Part 3 medical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Part 1b medical trial to review folks with superior strong and hematologic malignancies.
Beneficial Tales
This immediate information alert was generated by narrative science expertise and monetary information from MarketBeat to be able to present readers with the quickest and most correct reporting. This story was reviewed by MarketBeat’s editorial workforce previous to publication. Please ship any questions or feedback about this story to contact@marketbeat.com.
Earlier than you contemplate Arcus Biosciences, you may wish to hear this.
MarketBeat retains monitor of Wall Avenue’s top-rated and greatest performing analysis analysts and the shares they suggest to their purchasers each day. MarketBeat has recognized the 5 shares that prime analysts are quietly whispering to their purchasers to purchase now earlier than the broader market catches on… and Arcus Biosciences wasn’t on the checklist.
Whereas Arcus Biosciences at present has a “Average Purchase” ranking amongst analysts, top-rated analysts imagine these 5 shares are higher buys.
View The 5 Shares Right here
Click on the hyperlink under and we’ll ship you MarketBeat’s checklist of seven greatest retirement shares and why they need to be in your portfolio.
Get This Free Report
